136 related articles for article (PubMed ID: 33566186)
1. Interim 4'-[methyl-
Mitamura K; Norikane T; Yamamoto Y; Fujimoto K; Takami Y; Hoshikawa H; Toyohara J; Nishiyama Y
EJNMMI Res; 2021 Feb; 11(1):13. PubMed ID: 33566186
[TBL] [Abstract][Full Text] [Related]
2. Influence of volumetric 4'-[methyl-
Hoshikawa H; Mori T; Maeda Y; Takahashi S; Ouchi Y; Yamamoto Y; Nishiyama Y
Ann Nucl Med; 2017 Jan; 31(1):63-70. PubMed ID: 27679399
[TBL] [Abstract][Full Text] [Related]
3. Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma.
Ito K; Yokoyama J; Miyata Y; Toyohara J; Okasaki M; Minamimoto R; Morooka M; Ishiwata K; Kubota K
Nucl Med Commun; 2015 Mar; 36(3):219-25. PubMed ID: 25369751
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT.
Hotta M; Minamimoto R; Toyohara J; Nohara K; Nakajima K; Takase K; Yamada K
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2615-2623. PubMed ID: 33438100
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study.
Hotta M; Minamimoto R; Yamada K; Nohara K; Soma D; Nakajima K; Toyohara J; Takase K
EJNMMI Res; 2019 Jan; 9(1):10. PubMed ID: 30701347
[TBL] [Abstract][Full Text] [Related]
6.
Minamimoto R; Takeda Y; Hotta M; Toyohara J; Nakajima K; Naka G; Sugiyama H
EJNMMI Res; 2019 Jan; 9(1):4. PubMed ID: 30649637
[TBL] [Abstract][Full Text] [Related]
7. 4'-[methyl-
Fukuda Y; Yamamoto Y; Mitamura K; Ishikawa R; Asano E; Toyohara J; Norikane T; Nishiyama Y
Ann Nucl Med; 2019 Nov; 33(11):822-827. PubMed ID: 31401773
[TBL] [Abstract][Full Text] [Related]
8. [
Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
[No Abstract] [Full Text] [Related]
10. Texture indices of 4'-[methyl-
Ihara-Nishishita A; Norikane T; Mitamura K; Yamamoto Y; Fujimoto K; Takami Y; Ibuki E; Kudomi N; Hoshikawa H; Toyohara J; Nishiyama Y
Eur J Hybrid Imaging; 2020 Nov; 4(1):20. PubMed ID: 34191155
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
12. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
Minamimoto R; Toyohara J; Seike A; Ito H; Endo H; Morooka M; Nakajima K; Mitsumoto T; Ito K; Okasaki M; Ishiwata K; Kubota K
J Nucl Med; 2012 Feb; 53(2):199-206. PubMed ID: 22190643
[TBL] [Abstract][Full Text] [Related]
13. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma.
Albano D; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Apr; 33(4):280-287. PubMed ID: 30788775
[TBL] [Abstract][Full Text] [Related]
17.
Zhang P; Li Z; Wang D; Ma F; Zhang R; Liang W; Sun M; Fu Z; Sun X
Oncol Lett; 2018 Feb; 15(2):1845-1852. PubMed ID: 29434881
[TBL] [Abstract][Full Text] [Related]
18. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
[TBL] [Abstract][Full Text] [Related]
20. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer.
Kim KR; Shim HJ; Hwang JE; Cho SH; Chung IJ; Park KS; Kang SR; Kwon SY; Chung WK; Bae WK
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):170-178. PubMed ID: 28940101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
